The Pyruvate Dehydrogenase Kinase pipeline drugs market research report outlays comprehensive information on the Pyruvate Dehydrogenase Kinase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Pyruvate Dehydrogenase Kinase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Gastrointestinal, Infectious Disease, and Cardiovascular which include the indications Oncology, Lung Cancer, Inflammatory Bowel Disease, Pancreatitis, Sepsis, Bacterial Sepsis, Unspecified Cardiovascular Disorders, and Systolic Heart Failure. It also reviews key players involved in Pyruvate Dehydrogenase Kinase targeted therapeutics development with respective active and dormant or discontinued products.
The Pyruvate Dehydrogenase Kinase pipeline targets constitutes close to ten molecules. Out of which, approximately seven molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 1, 1, 3, and 2 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 1, and 2 molecule.
Pyruvate Dehydrogenase Kinase overview
Pyruvate dehydrogenase kinase (PDK) is a group of enzymes that are involved in regulating glucose metabolism and the conversion of pyruvate to acetyl-CoA within the mitochondria. The primary function of PDK is to inhibit the activity of the pyruvate dehydrogenase complex (PDC) by phosphorylating specific sites on the pyruvate dehydrogenase (PDH) enzyme, which is a key enzyme involved in the conversion of pyruvate to acetyl-CoA.
For a complete picture of Pyruvate Dehydrogenase Kinase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
